ALL
Pharma in China
Pharma Experts
Market News
Products Guide
Brand Story
-
Heron Therapeutics Announces FDA Approval of an Indication Expansion for Zynrelef for Postoperative Pain Management
December 14, 2021Heron Therapeutics, Inc. (Nasdaq: HRTX), a commercial-stage biotechnology company focused on improving the lives of patients by developing best-in-class treatments to address some of the most important unmet patient needs... -
Heron Therapeutics Announces Submission of HTX-019 NDA for the Prevention of Postoperative Nausea and Vomiting to FDA
November 22, 2021Heron Therapeutics, Inc. (Nasdaq: HRTX), a commercial-stage biotechnology company focused on improving the lives of patients by developing best-in-class treatments to address some of the most important unmet patient needs... -
Heron Receives FDA Extension of NDA Review Period for Postoperative Pain Treatment
March 09, 2020Heron Therapeutics announced the U.S. Food and Drug Administration (FDA) has extended the review period for the New Drug Application (NDA) for HTX-011 by up to three months. -
FDA Grants Priority Review Designation for HTX-011
January 03, 2019Heron Therapeutics announced the U.S. Food and Drug Administration (FDA) has accepted the new drug application (NDA) for Heron's investigational agent, HTX-011, and has granted it a Priority Review designation.....
Pharma Sources Insight January 2025
